Frequency of use of QT-interval prolonging drugs in psychiatry in Belgium

被引:0
|
作者
Eline Vandael
Thomas Marynissen
Johan Reyntens
Isabel Spriet
Joris Vandenberghe
Rik Willems
Veerle Foulon
机构
[1] KU Leuven – University of Leuven,Department of Pharmaceutical and Pharmacological Sciences, Clinical Pharmacology and Pharmacotherapy
[2] KU Leuven – University of Leuven,Department of Cardiovascular Sciences
[3] University Hospitals Leuven,Cardiology
[4] Sint-Jan Hospital,Pharmacy Department
[5] University Hospitals Leuven,Department of Neurosciences
[6] KU Leuven – University of Leuven,Psychiatry
[7] University Hospitals Leuven,undefined
关键词
Antidepressants; Antipsychotics; Belgium; Drug-induced QT-prolongation; Drug interactions; Psychiatry; Torsade de pointes;
D O I
暂无
中图分类号
学科分类号
摘要
Introduction Drug-induced QT-prolongation is an established risk factor for Torsade de pointes and sudden cardiac death. The list of QT-prolonging drugs is extensive and includes many drugs commonly used in psychiatry. Aim In this study we performed a cross-sectional analysis of medication profiles to assess the prevalence of drug interactions potentially leading to QT-prolongation. Setting 6 psychiatric hospitals in Flanders, Belgium. Methods For each patient, the full medication list was screened for the presence of interactions, with special attention to those with an increased risk for QT-prolongation. Current practice on QT monitoring and prevention of drug-induced arrhythmia was assessed. Main outcome measure Number of drug interactions with risk of QT-prolongation. Results 592 patients (46 % female; mean age 55.7 ± 17.1 years) were included in the analysis. 113 QT-prolonging interactions were identified in 43 patients (7.3 %). QT-prolonging interactions occurred most frequently with antidepressants (n = 102) and antipsychotics (n = 100). The precautions and follow-up provided by the different institutions when combining QT-prolonging drugs were very diverse. Conclusion Drug combinations that are associated with QT-prolongation are frequently used in the chronic psychiatric setting. Persistent efforts should be undertaken to provide caregivers with clear guidelines on how to use these drugs in a responsible and safe way.
引用
收藏
页码:757 / 765
页数:8
相关论文
共 50 条
  • [41] Evaluation of QT-Interval Prolongation: Detection of most Frequently Associated Drugs in Clinical Oncology
    Bagnes, C.
    Keller, G. A.
    Alvarez, P. A.
    Ponte, M. L.
    Belloso, W.
    Campos, A.
    Di Girolamo, G.
    DRUG SAFETY, 2011, 34 (10) : 960 - 960
  • [42] QT-INTERVAL RESPONSE TO EXERCISE IN CHILDREN WITH SYNCOPE
    SALIM, MA
    DISESSA, TG
    CLINICAL RESEARCH, 1993, 41 (04): : A782 - A782
  • [43] Qt-interval prolongation caused by healthfood products?
    Gittermann, M.
    SWISS MEDICAL WEEKLY, 2008, 138 : 35S - 35S
  • [44] FAMILIAL PROLONGATION OF THE QT-INTERVAL WITH AND WITHOUT DEAFNESS
    BUTT, H
    BERGHORN, K
    HERZ KREISLAUF, 1980, 12 (02): : 89 - 92
  • [45] Evaluation of QT-Interval Prolongation: Detection of Most Frequently Associated Drugs in Clinical Oncology
    Bagnes, C.
    Keller, G. A.
    Alvarez, P. A.
    Ponte, M. L.
    Belloso, W. H.
    Campos, A.
    Di Girolamo, G.
    DRUG SAFETY, 2012, 35 (10) : 899 - 900
  • [46] QT-INTERVAL MEASUREMENT - IMPORTANCE OF LEAD SELECTION
    COWAN, JC
    YUSOFF, K
    AMOS, PA
    GOLD, AE
    BOURKE, JP
    TANSUPHASWADIKUL, S
    CAMPBELL, RWF
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 1987, 10 (04): : 1027 - 1027
  • [47] BEZAFIBRATE DOES NOT INFLUENCE THE QT-INTERVAL IN MAN
    OLSSON, AG
    EKELUND, LG
    LANG, PD
    VOLLMAR, J
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1983, 5 (02) : 341 - 342
  • [50] QT-Interval Dispersion and Myocardial Viability Response
    Gadaleta, Francisco L.
    REVISTA ESPANOLA DE CARDIOLOGIA, 2009, 62 (04): : 462 - 463